

Top 5 Sponsor Accelerates Study Timeline with 30,000+ Enrollments in *Just 3 Months*

THE CHALLENGE

A top 5 pharmaceutical company initiated a global vaccine study to test the safety, tolerability, immunogenicity, and efficacy of their new molecular entity (NME)—one that would become critical to the masses. The client also required an ethnically diverse population for their vaccine trial in support of FDA and SAHPRA approval. The urgency to deliver speed and true outcomes was set upon a backdrop of lost healthcare jobs and a global public health emergency due to the novel coronavirus (COVID-19).

THE RESULTS

At the core of the results, sites were optimized to meet their full potential, delivering comprehensive recruitment, enrollment, and retention—without sacrificing data integrity. Moreover, the sponsor received an Emergency Use Authorization (EUA) in 10 months.

Global Support

68%

of global enrollments came through WCG supported sites

87%

of global enrollments included participants with diverse backgrounds

US Support

42%

of US enrollments came through WCG supported sites

30%

of US enrollments included participants with diverse backgrounds



“WCG enabled critical efficiency that allowed us to effectively support our investigative sites and meet aggressive research timelines.”

– VP, Top 5 Pharma


OUR SOLUTION



Launched a multi-channel media campaign to spread awareness



Developed a secure and easy-to-use website to receive inbound participant inquiries



Deployed our PIC (Participant Interaction Center) to follow-up with participants



Placed 225 CRCs in the first 6 weeks to enroll and retain participants